Literature DB >> 26376109

Protective effect of astragaloside IV on lipopolysaccharide-induced cardiac dysfunction via downregulation of inflammatory signaling in mice.

Peng Zhao1,2, Ying Wang2, Shan Zeng2, Jie Lu2, Tie-Min Jiang2, Yu-Ming Li2.   

Abstract

CONTEXT: Astragaloside IV (ASI) is a major and active saponin derivative of Astragalus membranaceus (Fisch) Bge. The anti-inflammatory properties of ASI are important for its cardioprotective effects. However, the molecular mechanisms of the protective effect of ASI on lipopolysaccharide (LPS)-induced cardiac dysfunction is yet to be elucidated.
OBJECTIVE: This study was designed to investigate the therapeutic effects and possible mechanisms of ASI against LPS-induced septic cardiac dysfunction and inflammation in mice.
MATERIALS AND METHODS: Mice were intraperitoneally injected with ASI (20 mg/kg) for 1 week before LPS challenge (10 mg/kg, i.p.). Left ventricular performance and morphology were analyzed using echocardiography 6 h after LPS induction. Activities of lactate dehydrogenase (LDH) in serum were measured and serum levels of cardiac troponin I (cTnI) were quantified by ELISA. Serum levels of tumor necrosis factor-α (TNF-α), monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6) and IL-1β were also quantified by ELISA. The protein expressions of NF-кB p65 and p-AKT in heart tissues were detected using Western blot analysis.
RESULTS: LPS administration deteriorated cardiac function and was attenuated by ASI pretreatment. ASI attenuated LPS-induced the increase of LDH and cTnI activities in mice. ASI also prevented NF-кB activation and subsequent myocardial inflammatory responses in endotoxemic mice. The effects of ASI were closely associated with the phosphatidylinositol-3-kinase (PI3K/AKT) signaling pathway, as characterized by ASI-induced activation in phospho-Akt. ASI also extended the lifespan of toxemic mice.
CONCLUSION: ASI significantly attenuated LPS-induced cardiac dysfunction and inflammatory mediator production by inhibiting NF-кB and activating PI3K/AKT signaling pathway.

Entities:  

Keywords:  Astragaloside IV; NF-кB; PI3K/Akt signaling; cardiac dysfunction; sepsis/septic shock

Mesh:

Substances:

Year:  2015        PMID: 26376109     DOI: 10.3109/08923973.2015.1080266

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  11 in total

1.  Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway.

Authors:  Xiaoqing Zhang; Huiyan Qu; Tao Yang; Qian Liu; Hua Zhou
Journal:  Cell Cycle       Date:  2022-06-30       Impact factor: 5.173

2.  Astragaloside IV ameliorates renal injury in db/db mice.

Authors:  Huili Sun; Wenjing Wang; Pengxun Han; Mumin Shao; Gaofeng Song; Heng Du; Tiegang Yi; Shunmin Li
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

3.  HP1330 Contributes to Streptococcus suis Virulence by Inducing Toll-Like Receptor 2- and ERK1/2-Dependent Pro-inflammatory Responses and Influencing In Vivo S. suis Loads.

Authors:  Qiang Zhang; Jingjing Huang; Junping Yu; Zhongmin Xu; Liang Liu; Yajing Song; Xiaomei Sun; Anding Zhang; Meilin Jin
Journal:  Front Immunol       Date:  2017-07-31       Impact factor: 7.561

4.  Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure.

Authors:  Bin Tang; Jin-Guo Zhang; Hong-Yong Tan; Xi-Qing Wei
Journal:  Biosci Rep       Date:  2018-05-22       Impact factor: 3.840

5.  Astragaloside IV alleviates the symptoms of experimental ulcerative colitis in vitro and in vivo.

Authors:  Suxiao Wu; Zilan Chen
Journal:  Exp Ther Med       Date:  2019-08-16       Impact factor: 2.447

6.  Exploring Molecular Mechanism of Huangqi in Treating Heart Failure Using Network Pharmacology.

Authors:  Yan-Gu Tao; Xiu-Fang Huang; Jun-Yan Wang; Meng-Ru Kang; Ling-Jun Wang; Shao-Xiang Xian
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-23       Impact factor: 2.629

7.  Protective Effects of Astragalus Polysaccharide on Sepsis-Induced Acute Kidney Injury.

Authors:  Jie Sun; Shanzhai Wei; Yilai Zhang; Jia Li
Journal:  Anal Cell Pathol (Amst)       Date:  2021-01-26       Impact factor: 2.916

8.  Acetyl-11-Keto-β-Boswellic Acid (AKBA) Prevents Lipopolysaccharide-Induced Inflammation and Cytotoxicity on H9C2 Cells.

Authors:  Danial Taherzadeh; Vafa Baradaran Rahimi; Hamed Amiri; Sajjad Ehtiati; Roghayeh Yahyazadeh; Seyed Isaac Hashemy; Vahid Reza Askari
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-30       Impact factor: 2.629

9.  Inhibition of miRNA-1-Mediated Inflammation and Autophagy by Astragaloside IV Improves Lipopolysaccharide-Induced Cardiac Dysfunction in Rats.

Authors:  Qiuning Wang; Weiying Chen; Xuefeng Yang; Ying Song; Xiaowei Sun; Guizhou Tao; Hong Wang; Nan Zhao; Yue Huang; Erqing Chai; Futian Tang
Journal:  J Inflamm Res       Date:  2022-04-23

Review 10.  Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders.

Authors:  Birgit Waltenberger; Andrei Mocan; Karel Šmejkal; Elke H Heiss; Atanas G Atanasov
Journal:  Molecules       Date:  2016-06-22       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.